PESG Research’s Post

Re-Evaluating PIN1 as a therapeutic target in oncology even with neutral, potent inhibitors and PROTACs, leaves the question unanswered still. "Whether PIN1 is a proper oncologic target " Though unfavorable evidence of PIN1 as an oncologic target based on findings from siRNA knock-down experiments from this study can possibly rest the case in peace. https://lnkd.in/g9MWqM-e

Review article by Xavier et al. discusses current progress in targeting the tumor micro environment for drug development https://lnkd.in/eK8kcryD #JIPO #TME #precisiononcology #microenvironment Innovative Oncology Network

What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference

Catalyst is Project Optimus ready, are you? Read more to discover how Catalyst Oncology has seen Project Optimus play out over the past year in study designs and Phase I operations. https://lnkd.in/gwunfdkP   #ConnectWithCatalyst #AACR #ProjectOptimus #OncologyDrugDevelopment

We’re presenting new and updated data from our broad oncology and hematology pipeline at #ASCO2024. Learn more about our presentations, which feature our novel investigational research approaches here: https://bit.ly/3QciEV9

Did you know that biomarkers can help show the effects of your treatment on a tumor and a patient’s response to your compound? As one of many methods used for early signal detection in oncology drug development programs, biomarkers can play a crucial role in the success of your trial. Learn more about the advantages and uses of biomarkers in our white paper: https://ow.ly/z3TU50RARo2

What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference

Just to make it painfully obvious, the goal is to detect HLA LOH in a somatic context - inside a tumor sample. Combined with HLA typing its a critical insight towards biomarker development and the comprehensive characterization of the tumor sample.

From statistics, drug research, to the funding of this targeted approach to cancer treatment, access the latest insights on Precision Oncology. Between 2019 and 2023, more than 10,000 clinical trials were conducted worldwide, with Precision Oncology accounting for 30% of them. This targeted approach is one of the most groundbreaking developments in recent medical history. Explore this comprehensive report from Novotech as they delve into the global clinical trial landscape. Learn more here: https://ow.ly/KxOg50RnilU. #PrecisionOncology #CancerTreatment #ClinicalTrials #NovotechReport #OncologyInsights

Many precision therapies benefit from the co-development of biomarkers with varying applications in clinical decision-making. However, oncology developers often face challenges integrating biomarkers into clinical trials. Read our whitepaper to learn how to de-risk biomarker selection and implementation. https://ow.ly/hSs750TFGLf